2015 American Transplant Congress
Non-Inferior Outcomes of Third and Fourth Renal Transplant. An Analysis of Our Experience
Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
INTRODUCTIONOutcome of third and subsequent renal transplants have not been associated with favorable outcomes. We analyze our experience in patients with three or more kidney-transplants…2015 American Transplant Congress
Kidney Paired Donation: National Activity and Perspectives
While utilization of Kidney Paired Donation (KPD) continues to increase, the potential is not fully realized. We surveyed kidney transplant (KTX) professionals to evaluate perceptions…2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…2015 American Transplant Congress
Measuring Affinity of Polyclonal HLA-Specific Antibodies in Highly Sensitised Cases Can Serve as an Additional Biomarker to Guide Direct Transplantation
Significant numbers of patients on transplant waiting lists in the UK are sensitised (43%). Direct transplantation across these HLA-specific antibodies using risk stratification strategies are…2015 American Transplant Congress
Differences in Reactivity of HLA-Specific Antibodies May Be Explained By Differences in Their Affinities for Selected Epitopes on HLA Proteins
Affinity of IgG immunoglobulins for antigen varies and matures within the evolution of immune responses. Affinity is likely to be different for different epitope-antibody interactions…2015 American Transplant Congress
Renal Outcomes of Cross Match Positive Simultaneous Liver Kidney (SLK) Transplant Recipients Compared to Cross Match Positive Kidney Allograft Recipients
The protective role of liver in cross-match(XM) positive SLK recipients and its impact on the incidence of renal antibody mediated rejection (AMR) is unclear.A retrospective…2015 American Transplant Congress
Incidence and Clinical Severity of Hypogammaglobulinemia (Hypo-IgG) in Highly-HLA Sensitized Patients (HS) Undergoing Desensitization (DES)
Introduction: Desensitization therapies (DES) have dramatically improved rates of transplantation among HS patients. However, antibody-reduction and B-cell/plasma cell directed therapies could have implications for humoral…2015 American Transplant Congress
Post-Kidney Transplant Infections in Desensitized Patients Receiving Thymoglobulin or Daclizumab Induction: Results of a Randomized Clinical Trial
Live donor kidney transplant recipients requiring desensitization for donor-specific antibody, who were enrolled in a single-center randomized trial of thymoglobulin vs. daclizumab induction, were evaluated…2015 American Transplant Congress
Infectious Complications in ABO Incompatible Kidney Transplantation Recipient According to the Rituximab Dose
BackgroundDesensitization with rituximab and intravenous immunoglobulin improves ABO incompatible (ABOi) kidney transplantation (KT) outcomes. However, infections have been noted in association with rituximab administration. In…2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…
American Transplant Congress abstracts